LION bioscience signed a contract acquiring Sygnis Bioscience. After that deal goes through, Axaron bioscience will assign its entire operating business to Sygnis Bioscience.
Axaron Bioscience, founded in 1997, develops therapies to treat neurodegenerative diseases. AX200, a product for the treatment of strokes, is the company’s most advanced compound and is currently being tested in a Phase IIa clinical trial.
Lion has been restructuring its operations since the end of 2004.